Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab + irinotecan in recurrent or refractory high‑grade glioma
2009-012582-64Phase 2Completed
- Sponsor
- Policlinico Gemelli
- Start
- May 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of bevacizumab and irinotecan in malignant glioma and high-grade glioma (HGG), sponsored by Policlinico Gemelli. Primary endpoint: Objective confirmed tumor response rate. Started May 2009; status: completed.
02
Drugs
bevacizumabirinotecan
03
Conditions
malignant gliomahigh-grade glioma (HGG)
Beyond the preview
Go deeper on 2009-012582-64.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-012582-64.